{
  "nctId": "NCT04340557",
  "briefTitle": "Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection",
  "officialTitle": "Randomized Open Label Study of Standard of Care Plus an Angiotensin II Receptor Blocker Compared to Standard of Care Alone to Minimize the Progression to Respiratory Failure in SARS-CoV-2 Infection",
  "protocolDocument": {
    "nctId": "NCT04340557",
    "filename": "Prot_SAP_000.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2020-04-20",
    "uploadDate": "2021-05-10T16:52",
    "size": 342588,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT04340557/document/Prot_SAP_000.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [
    "PHASE4"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "NONE",
  "enrollmentInfo": {
    "enrollmentCount": 31,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2020-03-27",
    "completionDate": "2020-06-13",
    "primaryCompletionDate": "2020-06-13",
    "firstSubmitDate": "2020-04-06",
    "firstPostDate": "2020-04-09"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Confirmed COVID-19 positive test result\n* Mild to moderate respiratory symptoms of COVID-19.\n* Systolic blood pressure â‰¥ 105 mmHg.\n* Screen within 3 days of a positive COVID-19 test.\n* Age â‰¥18 years old.\n* Access to a phone in the hospital room or an electronic device that is capable of receiving phone or video calls.\n* Able to read/write/speak English or Spanish fluently.\n* Subjects must have the capacity to provide consent or an appropriate LAR to provide informed consent.\n* Negative pregnancy test for women of childbearing potential and subject is randomized to the study arm.\n\nExclusion Criteria:\n\n* Severe allergy to any ARB or ACE-inhibitor, including angioedema\n* In the intensive care unit at screening.\n* Home meds include any kind of ACE inhibitor or ARB\n* Acute Kidney Injury (50% reduction in GFR from baseline at admission to any time during treatment in the study treatment arm)\n* Hyperkalemia \\>5.0 mmol/L at baseline or any time during treatment in the study treatment arm\n* Creatinine Clearance \\< 30 ml/min at baseline or any time during treatment in the study treatment arm",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Mechanical Ventilation",
        "description": "Number of subjects requiring transfer into ICU for mechanical ventilation due to respiratory failure",
        "timeFrame": "from date of patient admission to date of patient discharge or date of death, whichever came first, assessed up to 45 days"
      }
    ],
    "secondary": [
      {
        "measure": "ICU Transfer",
        "description": "Number of subjects transferred from non-ICU bed to an ICU bed",
        "timeFrame": "from date of patient admission to date of patient discharge or date of death, whichever came first, assessed up to 45 days"
      },
      {
        "measure": "Oxygen Therapy",
        "description": "Mean number of liters of oxygen consumed",
        "timeFrame": "from date of patient admission to date of patient discharge or date of death, whichever came first, assessed up to 45 days"
      }
    ],
    "other": [
      {
        "measure": "Length of Hospital Stay",
        "description": "Length of hospital stay from admission to discharge",
        "timeFrame": "from date of patient admission to date of patient discharge or date of death, whichever came first, assessed up to 45 days"
      },
      {
        "measure": "In Hospital Mortality",
        "description": "Number of subjects who expired while hospitalized",
        "timeFrame": "from date of patient admission to date of patient discharge or date of death, whichever came first, assessed up to 45 days"
      }
    ]
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 2,
      "otherCount": 2,
      "totalCount": 5
    },
    "studyDesign": {
      "phases": [
        "PHASE4"
      ],
      "isRandomized": true,
      "isMasked": false,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 38,
    "complexityCategory": "Moderate"
  },
  "collectionDate": "2025-09-22T02:30:37.898Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}